Gilead Sciences Inc. announced Thursday that it plans to partner with Mylan Inc., Ranbaxy Laboratories Ltd. and Strides Arcolab Ltd. "to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine in developing countries," the Wall Street Journal reports (Stevenson, 8/2). Gilead signed deals with the three Indian companies "to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug emtricitabine in developing countries," Reuters reports, noting that under the deals, Gilead "will provide technology and funding to help reduce manufacturing costs of the drug, the companies said" (Kuber, 8/2).